Pirfenidone News and Research

RSS

InterMune to launch Esbriet for German patients with IPF

InterMune, Inc. today announced that Esbriet will be offered to patients in Germany beginning September 15, 2011. This will mark the first time Esbriet will be commercially available in Europe since it was approved by the European Commission in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF), a devastating and fatal lung disease.

12 Sep 2011

Enrollment commences in InterMune's Esbriet Phase 3 study for IPF

InterMune today announced that patient enrollment has begun in ASCEND, a new Phase 3 study of pirfenidone for patients who suffer from idiopathic pulmonary fibrosis.

8 Jul 2011

Positive pirfenidone data in idiopathic pulmonary fibrosis to be presented at ATS conference

InterMune, Inc. today announced that an oral presentation and a poster presentation related to the company's development program for pirfenidone in idiopathic pulmonary fibrosis will be presented at the 2011 International Conference of the American Thoracic Society, being held in Denver May 13-18, 2011.

16 May 2011

The Lancet publishes two pirfenidone Phase 3 trial results in idiopathic pulmonary fibrosis

InterMune, Inc. today announced the publication of results from two Phase 3 trials demonstrating that treatment with pirfenidone, a novel antifibrotic and anti-inflammatory drug, was associated with favorable effects on lung function, 6-minute walk test distance and progression-free survival (PFS) in patients with mild to moderate idiopathic pulmonary fibrosis (IPF).

16 May 2011

JASN publishes positive results from pirfenidone study in diabetic nephropathy

Researchers at the University of California, San Diego School of Medicine, the National Institutes of Health and the Mayo Clinic have published promising results of a clinical study using an experimental anti-fibrotic and anti-inflammatory drug called pirfenidone to treat patients with diabetic nephropathy. Their study will be published in the April 21 issue of the Journal of the American Society of Nephrology.

22 Apr 2011

EC grants marketing authorization for InterMune's Esbriet to treat IPF

InterMune, Inc. today announced that the European Commission has granted marketing authorization for Esbriet. Esbriet is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis, a progressive and fatal lung disease.

3 Mar 2011

Today's opinions: Ariz. hospital and abortion; Wall Street Journal's issues with PolitiFact; Calif.'s anti-smoking success

St. Joseph's Hospital and Medical Center in Phoenix announced on Tuesday that it will continue to provide life-saving abortion care to patients even though it means losing its affiliation with the local Roman Catholic Diocese (12/23).

24 Dec 2010

CHMP recommends to grant marketing authorization for Espriet drug against PF to CPF

The Coalition for Pulmonary Fibrosis announced to more than 128,000 patients news that the first drug for the treatment of the deadly lung disease Pulmonary Fibrosis has passed a major hurdle in the European regulatory process and is likely to be approved in all 27 member countries of the European Union.

22 Dec 2010

InterMune's MAA for Esbriet receives positive CHMP opinion

InterMune, Inc. today announced additions to its senior leadership team to prepare for the commercialization of Esbriet™ (pirfenidone) in Europe. InterMune's Marketing Authorization Application (MAA) for Esbriet received a positive CHMP opinion that is now awaiting ratification by the European Commission.

20 Dec 2010

BIDMC, IPFnet to conduct clinical trials for idiopathic pulmonary fibrosis

Beth Israel Deaconess Medical Center (BIDMC) will join the Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet), a clinical research network sponsored by the National Heart Lung and Blood Institute (NHLBI) to conduct randomized clinical trials to evaluate new and existing medications for the treatment of idiopathic pulmonary fibrosis (IPF). The network is made up of healthcare institutions from around the United States.

16 Nov 2010

Cipla launches generic Pirfenidone for IPF

Cipla, among the world's leading generic pharmaceutical companies, has introduced Pirfenidone in India under the brand name Pirfenex, for the treatment of IPF. A chronic progressive form of lung disease, IPF has average survival rates as low as 3-5 years which is less than many cancers. Till now there is no approved treatment for IPF.

20 Oct 2010

Roche receives development and commercialization rights for danoprevir drug

InterMune, Inc. today announced that it has sold worldwide development and commercialization rights to danoprevir (also known as RG7227 or ITMN-191) to Hoffman-La Roche Inc. and F. Hoffman-La Roche Ltd. for $175 million in cash.

7 Oct 2010

InterMune's development program for pirfenidone, IPF to be presented at Annual Congress of ERS

InterMune, Inc. today announced that four oral presentations related to the company's development program for pirfenidone and idiopathic pulmonary fibrosis will be presented at the Annual Congress of the European Respiratory Society, to be held September 18-22 in Barcelona, Spain.

13 Sep 2010

InterMune second-quarter total revenue decreases to $5.9 million

InterMune, Inc. today announced results from operations for the second quarter and six months ended June 30, 2010. InterMune also highlighted its recent clinical development and business activities, and provided forward-looking financial guidance for 2010.

28 Jul 2010

Data on Qnexa to be presented at World Congress on CODHy in Prague

VIVUS, Inc. today announced that data on Qnexa, an investigational drug candidate, will be presented at the 3rd World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension in Prague, Czech Republic.

13 May 2010

Stereotaxis to be featured prominently in 31st HRS

Stereotaxis' safety and efficacy in the treatment of patients with complex arrhythmias such as atrial fibrillation, ventricular tachycardia, and congenital heart defects will be featured prominently in the scientific program of the 31st Annual Heart Rhythm Scientific Sessions in Denver, Colorado. Eight podium presentations and eight posters will underscore the broad clinical leadership that Stereotaxis has achieved in the treatment of patients with complex cardiac arrhythmias.

13 May 2010

Graymark Healthcare first-quarter consolidated net revenues increase 7% to $27.6 million

Graymark Healthcare, Inc. today announced progress on Fiscal 2010 Initiatives and financial results for the Quarter ending March 31, 2010.

13 May 2010

PAREXEL further expands presence in China with offices in Chengdu and Guangzhou

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that the Company has opened offices in Chengdu and Guangzhou, China to support a growing requirement for a broad range of clinical development and regulatory consulting capabilities in the country and throughout the Asia/Pacific region.

From Parexel 13 May 2010

Solta Medical honored with Provectus Award at first annual Bright Lights Conference

Solta Medical, Inc., a global leader in the medical aesthetics market, today announced that it has received the Provectus Award presented by MDB Capital Group at the first annual Bright Lights Conference, the first public company conference to focus exclusively on companies with disruptive and market changing intellectual property (IP).

13 May 2010

Amira Pharmaceuticals' LPA1 receptor antagonist program data published in British Journal of Pharmacology

Amira Pharmaceuticals, Inc. announced today that preclinical data from its LPA1 receptor antagonist program has been published in the British Journal of Pharmacology.

7 May 2010

Pirfenidone News and Research

InterMune to launch Esbriet for German patients with IPF

Enrollment commences in InterMune's Esbriet Phase 3 study for IPF

Positive pirfenidone data in idiopathic pulmonary fibrosis to be presented at ATS conference

The Lancet publishes two pirfenidone Phase 3 trial results in idiopathic pulmonary fibrosis

JASN publishes positive results from pirfenidone study in diabetic nephropathy

EC grants marketing authorization for InterMune's Esbriet to treat IPF

Today's opinions: Ariz. hospital and abortion; Wall Street Journal's issues with PolitiFact; Calif.'s anti-smoking success

CHMP recommends to grant marketing authorization for Espriet drug against PF to CPF

InterMune's MAA for Esbriet receives positive CHMP opinion

BIDMC, IPFnet to conduct clinical trials for idiopathic pulmonary fibrosis

Cipla launches generic Pirfenidone for IPF

Roche receives development and commercialization rights for danoprevir drug

InterMune's development program for pirfenidone, IPF to be presented at Annual Congress of ERS

InterMune second-quarter total revenue decreases to $5.9 million

Data on Qnexa to be presented at World Congress on CODHy in Prague

Stereotaxis to be featured prominently in 31st HRS

Graymark Healthcare first-quarter consolidated net revenues increase 7% to $27.6 million

PAREXEL further expands presence in China with offices in Chengdu and Guangzhou

Solta Medical honored with Provectus Award at first annual Bright Lights Conference

Amira Pharmaceuticals' LPA1 receptor antagonist program data published in British Journal of Pharmacology

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News